Vivos INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
RDGL
Vivos INC10-K: Vivos Inc. Reports Annual Results for 2024, Highlights Progress in Radionuclide Therapy Development
Vivos Inc.'s 2024 annual report details ongoing efforts in developing its RadioGel technology and expanding its IsoPet veterinary services, despite facing financial challenges and expressing doubt about its ability to continue as a going concern.
OQB
RDGL
Vivos INCVivos Inc.'s annual report details the company's focus on its RadioGel technology for cancer treatment, progress in the veterinary market with IsoPet, and ongoing efforts to secure FDA approval for human trials.